In the meantime, William Blair initiated its Structure Therapeutics Inc ADR [GPCR] rating to an Outperform in a research note published recently. A number of analysts have revised their coverage, including Stifel’s analysts, who began to cover the stock in early January with a ‘”a Buy”‘ rating. H.C. Wainwright began covering GPCR with “Buy” recommendation on December 04, 2024. Morgan Stanley started covering the stock on September 23, 2024. It rated GPCR as “an Overweight”.
Price Performance Review of GPCR
On Tuesday, Structure Therapeutics Inc ADR [NASDAQ:GPCR] saw its stock jump 9.70% to $25.91. Over the last five days, the stock has gained 12.46%. Structure Therapeutics Inc ADR shares have fallen nearly -4.46% since the year began. Nevertheless, the stocks have fallen -33.53% over the past one year. While a 52-week high of $62.74 was reached on 01/31/25, a 52-week low of $13.22 was recorded on 04/09/25. SMA at 50 days reached $20.59, while 200 days put it at $31.42.
Levels Of Support And Resistance For GPCR Stock
The 24-hour chart illustrates a support level at 24.59, which if violated will result in even more drops to 23.28. On the upside, there is a resistance level at 26.74. A further resistance level may holdings at 27.57. The Relative Strength Index (RSI) on the 14-day chart is 71.39, which indicates overbought technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 3.66, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 2.61%. Stochastics %K at 94.07% indicates the stock is a selling.
How much short interest is there in Structure Therapeutics Inc ADR?
A steep rise in short interest was recorded in Structure Therapeutics Inc ADR stocks on 2025-04-15, dropping by 17947.0 shares to a total of 7.02 million shares. Yahoo Finance data shows the prior-month short interest on 2025-03-14 was 7.04 million shares. There was a decline of -0.26%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on May 21, 2024 when JP Morgan began covering the stock and recommended ‘”an Overweight”‘ rating along with a $65 price target.
